
According to Benzinga Pro, during Q4, eFFECTOR Therapeutics (NASDAQ:EFTR) earned $19.05 million, a 114.54% increase from the preceding quarter. eFFECTOR Therapeutics's sales decreased to $311.00 thousand, a 27.17% change since Q3. In Q3, eFFECTOR Therapeutics brought in $427.00 thousand in sales but only earned $8.88 million.